Compare SCHL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | ARVN |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 875.2M | 781.0M |
| IPO Year | 1995 | 2018 |
| Metric | SCHL | ARVN |
|---|---|---|
| Price | $33.93 | $13.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 21 |
| Target Price | ★ $37.00 | $15.71 |
| AVG Volume (30 Days) | 371.8K | ★ 749.6K |
| Earning Date | 03-23-2026 | 05-27-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,487,100,000.00 | $262,600,000.00 |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.77 | $5.90 |
| 52 Week High | $36.24 | $14.22 |
| Indicator | SCHL | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 54.65 |
| Support Level | $27.31 | $11.07 |
| Resistance Level | $35.89 | $13.97 |
| Average True Range (ATR) | 1.25 | 0.75 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 64.27 | 77.68 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.